SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that
management plans to report its third quarter 2020 financial results
on Tuesday, November 10, 2020, after the close of the U.S.
financial markets. Following the announcement, members of the
management team will host a conference call and webcast to discuss
the results and provide a general corporate update at 4:30
p.m. ET (1:30 p.m. PT).
To access the live call by phone please dial (877) 735-2860
(domestic) or (602) 563-8791 (international); the conference ID is
5504037. A live audio webcast of the event may also be accessed
through the "Investors" section of CTI's website at
www.ctibiopharma.com. A replay of the webcast will be available for
30 days following the event.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition,
development and commercialization of novel targeted therapies for
blood-related cancers that offer a unique benefit to patients and
their healthcare providers. We concentrate our efforts on
treatments that target blood-related cancers where there is an
unmet medical need. In particular, we are focused on evaluating
pacritinib, our sole product candidate currently in active
development, for the treatment of adult patients with
myelofibrosis. In addition, we have recently started developing
pacritinib for use in hospitalized patients with severe COVID-19,
in response to the COVID-19 pandemic. We are headquartered in
Seattle, Washington.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan
Meyers
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-third-quarter-2020-financial-results-on-november-10-2020-301165190.html
SOURCE CTI BioPharma Corp.